{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:16:02Z","timestamp":1787987762338,"version":"build-2784847793"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-026-03799-6","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:52:53Z","timestamp":1774086773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Beyond glomeruli: interstitial fibrosis and tubular atrophy predict poor renal outcomes in lupus nephritis"],"prefix":"10.1186","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0034-2270","authenticated-orcid":false,"given":"Paola","family":"Vidal-Montal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1614-8064","authenticated-orcid":false,"given":"Javier","family":"Narvaez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4340-6989","authenticated-orcid":false,"given":"Francesca","family":"Mitjavila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1974-9874","authenticated-orcid":false,"given":"Xavier","family":"Fulladosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5517-7482","authenticated-orcid":false,"given":"Olga","family":"Capdevila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1135-7588","authenticated-orcid":false,"given":"Joan","family":"Torras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Gom\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2358-6767","authenticated-orcid":false,"given":"Joan M","family":"Nolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"3799_CR1","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41584-024-01158-w","volume":"20","author":"J Lichtnekert","year":"2024","unstructured":"Lichtnekert J, Anders HJ. Lupus nephritis-related chronic kidney disease. Nat Rev Rheumatol. 2024;20:699\u2013711.","journal-title":"Nat Rev Rheumatol"},{"key":"3799_CR2","doi-asserted-by":"publisher","first-page":"e3443","DOI":"10.1097\/MD.0000000000002891","volume":"95","author":"M Galindo-Izquierdo","year":"2016","unstructured":"Galindo-Izquierdo M, Rodr\u00edguez-Almaraz E, Pego-Reigosa JM, L\u00f3pez-Longo FJ, Calvo-Al\u00e9n J, Oliv\u00e9 A, et al. Characterization of patients with lupus nephritis included in a large cohort from the Spanish Society of Rheumatology Registry of Patients with Systemic Lupus Erythematosus (RELESSER). Med (Baltim). 2016;95:e3443.","journal-title":"Med (Baltim)"},{"key":"3799_CR3","doi-asserted-by":"publisher","first-page":"e001375","DOI":"10.1136\/lupus-2024-001375","volume":"12","author":"P Vidal-Montal","year":"2025","unstructured":"Vidal-Montal P, Narv\u00e1ez J, Fulladosa X, Mitjavila F, Capdevila O, Torras J, et al. Outcomes following immunosuppressive therapy withdrawal after complete renal response in proliferative lupus nephritis. Lupus Sci Med. 2025;12:e001375.","journal-title":"Lupus Sci Med"},{"key":"3799_CR4","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1093\/rheumatology\/keab373","volume":"61","author":"M Zen","year":"2022","unstructured":"Zen M, Fuzzi E, Loredo Martinez M, Depascale R, Fredi M, Gatto M, et al. Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis. Rheumatology (Oxford). 2022;61:688\u201395.","journal-title":"Rheumatology (Oxford)"},{"issue":"4 Suppl 78","key":"3799_CR5","first-page":"S75","volume":"31","author":"G Moroni","year":"2013","unstructured":"Moroni G, Longhi S, Giglio E, Messa P, Ponticelli C. What happens after complete withdrawal of therapy in patients with lupus nephritis. Clin Exp Rheumatol. 2013;31(4 Suppl 78):S75\u201381.","journal-title":"Clin Exp Rheumatol"},{"key":"3799_CR6","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1136\/annrheumdis-2022-222435","volume":"81","author":"N Jourde-Chiche","year":"2022","unstructured":"Jourde-Chiche N, Costedoat-Chalumeau N, Baumstarck K, Loundou A, Bouillet L, Burtey S, et al. Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial. Ann Rheum Dis. 2022;81:1420\u20137.","journal-title":"Ann Rheum Dis"},{"key":"3799_CR7","doi-asserted-by":"publisher","unstructured":"Panagiotopoulos A, Kapsia E, El Michelakis I, Boletis J, Marinaki S, Sfikakis PP et al. Immunosuppressives discontinuation after renal response in lupus nephritis: predictors of flares, time to withdrawal and long-term outcomes. Rheumatol (Oxford) 2024 Jul 22:keae381. https:\/\/doi.org\/10.1093\/rheumatology\/keae381. Online ahead of print.","DOI":"10.1093\/rheumatology\/keae381"},{"key":"3799_CR8","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/S2665-9913(23)00320-X","volume":"6","author":"EF Chakravarty","year":"2024","unstructured":"Chakravarty EF, Utset T, Kamen DL, Contreras G, McCune WJ, Aranow C, et al. Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial. Lancet Rheumatol. 2024;6:e168\u201377.","journal-title":"Lancet Rheumatol"},{"key":"3799_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3109\/03009749409103047","volume":"23","author":"JL Pablos","year":"1994","unstructured":"Pablos JL, Gutierrez-Millet V, Gomez-Reino JJ. Remission of lupus nephritis with cyclophosphamide and late relapses following therapy withdrawal. Scand J Rheumatol. 1994;23:142\u20134.","journal-title":"Scand J Rheumatol"},{"key":"3799_CR10","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/ndt\/gfk073","volume":"21","author":"G Moroni","year":"2006","unstructured":"Moroni G, Gallelli B, Quaglini S, Banfi G, Rivolta E, Messa P, et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transpl. 2006;21:1541\u20138.","journal-title":"Nephrol Dial Transpl"},{"key":"3799_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000511268","volume":"145","author":"E Morales","year":"2021","unstructured":"Morales E, Galindo M, Trujillo H, Praga M. Update on lupus nephritis: looking for a new vision. Nephron. 2021;145:1\u201313.","journal-title":"Nephron"},{"key":"3799_CR12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","volume":"55","author":"JG Hanly","year":"2016","unstructured":"Hanly JG, O\u2019Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2016;55:252\u201362.","journal-title":"Rheumatology (Oxford)"},{"key":"3799_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/01.ASN.0000108969.21691.5D","volume":"15","author":"JJ Weening","year":"2004","unstructured":"Weening JJ, D\u2019Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241\u201350.","journal-title":"J Am Soc Nephrol"},{"key":"3799_CR14","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","volume":"93","author":"IM Bajema","year":"2018","unstructured":"Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, et al. Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93:789\u201396.","journal-title":"Kidney Int"},{"key":"3799_CR15","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1093\/ndt\/gfac286","volume":"38","author":"MD Duong","year":"2023","unstructured":"Duong MD, Wang S, Schwartz D, Mowrey WB, Broder A, Goilav B, et al. Total cortical interstitial inflammation predicts chronic kidney disease progression in patients with lupus nephritis. Nephrol Dial Transpl. 2023;38:1469\u201376.","journal-title":"Nephrol Dial Transpl"},{"key":"3799_CR16","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1177\/09612033231151597","volume":"32","author":"J Rodelo","year":"2023","unstructured":"Rodelo J, Aguirre L, Orteg\u00f3n K, Ust\u00e1riz J, Calderon L, Taborda A, et al. Predicting kidney outcomes among Latin American patients with lupus nephritis: the prognostic value of interstitial fibrosis and tubular atrophy and tubulointerstitial inflammation. Lupus. 2023;32:411\u201323.","journal-title":"Lupus"},{"key":"3799_CR17","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s40620-021-01007-z","volume":"34","author":"MF Gomes","year":"2021","unstructured":"Gomes MF, Mardones C, Xipell M, Blasco M, Sol\u00e9 M, Espinosa G, et al. The extent of tubulointerstitial inflammation is an independent predictor of renal survival in lupus nephritis. J Nephrol. 2021;34:1897\u2013905.","journal-title":"J Nephrol"},{"key":"3799_CR18","doi-asserted-by":"publisher","first-page":"13654","DOI":"10.3390\/ijms232214317","volume":"23","author":"S Sciascia","year":"2022","unstructured":"Sciascia S, Cozzi M, Barinotti A, Radin M, Cecchi I, Fenoglio R, et al. Renal fibrosis in lupus nephritis. Int J Mol Sci. 2022;23:13654.","journal-title":"Int J Mol Sci"},{"key":"3799_CR19","first-page":"e000899","volume":"10","author":"C Leatherwood","year":"2023","unstructured":"Leatherwood C, Speyer CB, Feldman CH, G\u00f3mez-Puerta JA, Hoover PJ, Waikar SS, et al. Clinical characteristics and renal prognosis associated with interstitial fibrosis and tubular atrophy (IFTA) and vascular injury in lupus nephritis biopsies. Lupus Sci Med. 2023;10:e000899.","journal-title":"Lupus Sci Med"},{"key":"3799_CR20","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1093\/rheumatology\/keae226","volume":"63","author":"YS Sun","year":"2024","unstructured":"Sun YS, Huang DF, Chang FP, Chen WS, Liao HT, Chen MH, et al. Interstitial fibrosis increases the risk of end-stage kidney disease in patients with lupus nephritis. Rheumatology (Oxford). 2024;63:1357\u201366.","journal-title":"Rheumatology (Oxford)"},{"key":"3799_CR21","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1002\/art.40575","volume":"70","author":"A Londo\u00f1o Jimenez","year":"2018","unstructured":"Londo\u00f1o Jimenez A, Mowrey WB, Putterman C, Buyon J, Goilav B, Broder A. Brief report: tubulointerstitial damage in lupus nephritis: A comparison of the factors associated with tubulointerstitial inflammation and renal scarring. Arthritis Rheumatol. 2018;70:1801\u20136.","journal-title":"Arthritis Rheumatol"},{"key":"3799_CR22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.semarthrit.2017.07.007","volume":"47","author":"A Broder","year":"2018","unstructured":"Broder A, Mowrey WB, Khan HN, Jovanovic B, Londo\u00f1o-Jimenez A, Izmirly P, et al. Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: A retrospective cohort study. Semin Arthritis Rheum. 2018;47:545\u201351.","journal-title":"Semin Arthritis Rheum"},{"key":"3799_CR23","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1177\/0961203313507986","volume":"22","author":"AO Alsuwaida","year":"2013","unstructured":"Alsuwaida AO. Interstitial inflammation and long-term renal outcomes in lupus nephritis. Lupus. 2013;22:1446\u201354.","journal-title":"Lupus"},{"key":"3799_CR24","doi-asserted-by":"publisher","first-page":"e15444","DOI":"10.1111\/1756-185X.15444","volume":"27","author":"H Jeong","year":"2024","unstructured":"Jeong H, Choi SE, Kang JH, Lee JS, Choi YD, Park DJ, et al. Coexisting tubulointerstitial inflammation and damage is a risk factor for chronic kidney disease in patients with lupus nephritis. Int J Rheum Dis. 2024;27:e15444.","journal-title":"Int J Rheum Dis"},{"key":"3799_CR25","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","volume":"79","author":"A Fanouriakis","year":"2020","unstructured":"Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79:713\u201323.","journal-title":"Ann Rheum Dis"},{"key":"3799_CR26","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1177\/0961203318776109","volume":"27","author":"B Obri\u0219c\u0103","year":"2018","unstructured":"Obri\u0219c\u0103 B, Jurubi\u021b\u0103 R, Andronesi A, Sorohan B, Achim C, Bobeica R, et al. Histological predictors of renal outcome in lupus nephritis: the importance of tubulointerstitial lesions and scoring of glomerular lesions. Lupus. 2018;27:1455\u201363.","journal-title":"Lupus"},{"key":"3799_CR27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ard.2025.09.007","volume":"85","author":"A Fanouriakis","year":"2026","unstructured":"Fanouriakis A, Kostopoulou M, Anders HJ, Andersen J, Aringer M, Beresford MW, et al. EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update. Ann Rheum Dis. 2026;85:75\u201390.","journal-title":"Ann Rheum Dis"},{"key":"3799_CR28","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1002\/art.43212","volume":"77","author":"LR Sammaritano","year":"2025","unstructured":"Sammaritano LR, Askanase A, Bermas BL, Dall\u2019Era M, Duarte-Garc\u00eda A, Hiraki LT, et al. 2024 American College of Rheumatology guideline for the screening, treatment, and management of lupus nephritis. Arthritis Rheumatol. 2025;77:1115\u201335.","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 1","key":"3799_CR29","first-page":"S1","volume":"105","author":"Kidney Disease","year":"2024","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 clinical practice guideline for the management of lupus nephritis. Kidney Int. 2024;105(Suppl 1):S1\u201369.","journal-title":"Kidney Int"},{"key":"3799_CR30","first-page":"82","volume":"28","author":"M Xipell","year":"2021","unstructured":"Xipell M, Egan A, Lled\u00f3 G, Villarreal JZ, Espinosa G, Garc\u00eda-Herrera A, et al. Understanding tubulointerstitial injury and repair mechanisms paves the way for renal outcome improvement in lupus nephritis. Rev Colomb Reumatol. 2021;28:82\u20139.","journal-title":"Rev Colomb Reumatol"},{"key":"3799_CR31","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.semnephrol.2015.08.007","volume":"35","author":"MR Clark","year":"2015","unstructured":"Clark MR, Trotter K, Chang A. The pathogenesis and therapeutic implications of tubulointerstitial inflammation in human lupus nephritis. Semin Nephrol. 2015;35:455\u201364.","journal-title":"Semin Nephrol"},{"key":"3799_CR32","doi-asserted-by":"publisher","first-page":"103014","DOI":"10.1016\/j.autrev.2021.103014","volume":"21","author":"M de Cos","year":"2022","unstructured":"de Cos M, Xipell M, Garc\u00eda-Herrera A, Lledo GM, Guillen E, Blasco M, et al. Assessing and counteracting fibrosis is a cornerstone of the treatment of CKD secondary to systemic and renal limited autoimmune disorders. Autoimmun Rev. 2022;21:103014.","journal-title":"Autoimmun Rev"},{"key":"3799_CR33","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/HYPERTENSIONAHA.119.11684","volume":"75","author":"CS Wilcox","year":"2020","unstructured":"Wilcox CS. Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors. Hypertension. 2020;75:894\u2013901.","journal-title":"Hypertension"},{"key":"3799_CR34","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.kint.2018.05.002","volume":"94","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Nakano D, Guan Y, Hitomi H, Uemura A, Masaki T, et al. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney Int. 2018;94:524\u201335.","journal-title":"Kidney Int"},{"key":"3799_CR35","doi-asserted-by":"publisher","first-page":"e29486","DOI":"10.1016\/j.heliyon.2024.e29486","volume":"10","author":"J Hu","year":"2024","unstructured":"Hu J, Teng J, Hui S, Liang L. SGLT-2 inhibitors as novel treatments of multiple organ fibrosis. Heliyon. 2024;10:e29486.","journal-title":"Heliyon"},{"key":"3799_CR36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/BOR.0000000000001002","volume":"36","author":"BR Wagner","year":"2024","unstructured":"Wagner BR, Rao PS. Sodium-glucose cotransporter 2 inhibitors: are they ready for prime time in the management of lupus nephritis? Curr Opin Rheumatol. 2024;36:163\u20138.","journal-title":"Curr Opin Rheumatol"},{"key":"3799_CR37","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1136\/annrheumdis-2022-222512","volume":"81","author":"E Morales","year":"2022","unstructured":"Morales E, Galindo M. SGLT2 inhibitors in lupus nephropathy, a new therapeutic strategy for nephroprotection. Ann Rheum Dis. 2022;81:1337\u20138.","journal-title":"Ann Rheum Dis"},{"key":"3799_CR38","doi-asserted-by":"publisher","first-page":"113236","DOI":"10.1016\/j.biopha.2022.113236","volume":"152","author":"F Yang","year":"2022","unstructured":"Yang F, Luo X, Li J, Lei Y, Zeng F, Huang X, et al. Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases. Biomed Pharmacother. 2022;152:113236.","journal-title":"Biomed Pharmacother"},{"key":"3799_CR39","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3389\/fphar.2020.00967","volume":"11","author":"D Kawanami","year":"2020","unstructured":"Kawanami D, Takashi Y. GLP-1 Receptor agonists in diabetic kidney disease: from clinical outcomes to mechanisms. Front Pharmacol. 2020;11:967.","journal-title":"Front Pharmacol"},{"key":"3799_CR40","doi-asserted-by":"publisher","unstructured":"Nugroho P. Improving renal protection in chronic kidney disease associated with type 2 diabetes: the role of finerenone. Endocr Metab Immune Disord Drug Targets 2025 Jan 8. https:\/\/doi.org\/10.2174\/0118715303350851241021105850. Online ahead of print.","DOI":"10.2174\/0118715303350851241021105850"},{"key":"3799_CR41","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.pcd.2024.09.001","volume":"18","author":"N Kanumilli","year":"2024","unstructured":"Kanumilli N, Miszon M, Schnell O, Groop PH. The role of finerenone in the management of CKD in T2D. Practical considerations for primary care. Prim Care Diabetes. 2024;18:565\u201373.","journal-title":"Prim Care Diabetes"},{"key":"3799_CR42","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrneph.2016.48","volume":"12","author":"XM Meng","year":"2016","unstructured":"Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-\u03b2: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12:325\u201338.","journal-title":"Nat Rev Nephrol"},{"key":"3799_CR43","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.xphs.2024.11.020","volume":"114","author":"D Yu","year":"2025","unstructured":"Yu D, Zhang R, Zhou J, Guo P, Li P, Ye M, et al. Pharmacokinetics and safety of pirfenidone in individuals with chronic kidney disease stage G2 and G3a: A single-dose, Phase I, bridging study. J Pharm Sci. 2025;114:1087\u201394.","journal-title":"J Pharm Sci"},{"key":"3799_CR44","doi-asserted-by":"publisher","first-page":"906","DOI":"10.2215\/CJN.01050207","volume":"2","author":"ME Cho","year":"2007","unstructured":"Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2007;2:906\u201313.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3799_CR45","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1681\/ASN.2010101049","volume":"22","author":"K Sharma","year":"2011","unstructured":"Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, Dunn SR, et al. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol. 2011;22:1144\u201351.","journal-title":"J Am Soc Nephrol"},{"key":"3799_CR46","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000519495","volume":"146","author":"L Bi","year":"2022","unstructured":"Bi L, Huang Y, Li J, Yang X, Hou G, Zhai P, Zhang Q, et al. Pirfenidone attenuates renal tubulointerstitial fibrosis through inhibiting miR-21. Nephron. 2022;146:110\u201320.","journal-title":"Nephron"},{"key":"3799_CR47","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.7150\/ijbs.101548","volume":"21","author":"Q Hong","year":"2025","unstructured":"Hong Q, Kim H, Cai GY, Chen XM, He JC, Lee K, et al. Modulation of TGF-\u03b2 signaling new approaches toward kidney disease and fibrosis therapy. Int J Biol Sci. 2025;21:1649\u201365.","journal-title":"Int J Biol Sci"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-026-03799-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03799-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03799-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:03:18Z","timestamp":1777514598000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-026-03799-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3799"],"URL":"https:\/\/doi.org\/10.1186\/s13075-026-03799-6","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"21 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Delarations"}},{"value":"This study was approved by our institutional ethics committee (Clinical Research Ethics Committee of Bellvitge University Hospital-IDIBELL). This study was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference for Harmonization.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}